ITRM20090369A1 - ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES - Google Patents
ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES Download PDFInfo
- Publication number
- ITRM20090369A1 ITRM20090369A1 IT000369A ITRM20090369A ITRM20090369A1 IT RM20090369 A1 ITRM20090369 A1 IT RM20090369A1 IT 000369 A IT000369 A IT 000369A IT RM20090369 A ITRM20090369 A IT RM20090369A IT RM20090369 A1 ITRM20090369 A1 IT RM20090369A1
- Authority
- IT
- Italy
- Prior art keywords
- ikk
- alpha
- inhibits
- amino acid
- acyl derivative
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 3
- 230000001684 chronic effect Effects 0.000 title description 3
- 230000004054 inflammatory process Effects 0.000 title description 3
- 230000001154 acute effect Effects 0.000 title 1
- 102000001284 I-kappa-B kinase Human genes 0.000 claims description 24
- 108060006678 I-kappa-B kinase Proteins 0.000 claims description 24
- 229940024606 amino acid Drugs 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000003047 N-acetyl group Chemical group 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- CBQJSKKFNMDLON-JTQLQIEISA-M N-acetyl-L-phenylalaninate Chemical compound CC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-M 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 3
- PMMURAAUARKVCB-KAZBKCHUSA-N (2r,4r,5s,6r)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound OC[C@H]1O[C@@H](O)C[C@@H](O)[C@@H]1O PMMURAAUARKVCB-KAZBKCHUSA-N 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 102000006947 Histones Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 229960005190 phenylalanine Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000009471 action Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
Description
MOLECOLA ANTAGONISTA DI PROCESSI INFTAMMATORT ACUTT E CRONICI ANTAGONIST MOLECULE OF ACUTT AND CHRONIC INFTAMMATORT PROCESSES
L'invenzione à ̈ relativa ad una molecola che risulta essere antagonista di processi infiammatori acuti e cronici: si tratta cioà ̈ di un inibitore selettivo della chinasi IKK alfa. The invention relates to a molecule that appears to be an antagonist of acute and chronic inflammatory processes: that is, it is a selective inhibitor of the IKK alpha kinase.
Come à ̈ noto, la risposta infiammatoria richiede l'attivazione coordinata di vari percorsi segnalatori che regolano l'espressione di mediatori pro-infiammatori ed il reclutamento dei leucociti; As is known, the inflammatory response requires the coordinated activation of various signaling pathways that regulate the expression of pro-inflammatory mediators and the recruitment of leukocytes;
svolge anche un ruolo importante nel preparare la risposta immunitaria adattativa per generare la memoria immunologi ca. it also plays an important role in preparing the adaptive immune response to generate immunological memory.
Per facilitare ulteriormente la comprensione del trovato, à ̈ necessario anche tenere presente che il percorso dell' NFKB (Nuclear Factor KB) viene ritenuto fortemente implicato nella patogenesi sia delle malattie infiammatorie croniche che delle patologie autoimmuni. NFKB appare svolgere un ruolo pleiotropico nelle risposte immunitarie ed infiammatorie- NFKB à ̈ un termine generico per una famìglia di fattori di trascrizione che svolgono un ruolo cruciale nell'infiammazione e nell'immunità . Questi fattori di trascrizione sono mantenuti inattivi nel citoplasma cellulare dal legame con IKB (inibitore di NFKB). To further facilitate the understanding of the invention, it is also necessary to keep in mind that the pathway of NFKB (Nuclear Factor KB) is considered to be strongly involved in the pathogenesis of both chronic inflammatory diseases and autoimmune diseases. NFKB appears to play a pleiotropic role in immune and inflammatory responses - NFKB is an umbrella term for a family of transcription factors that play a crucial role in inflammation and immunity. These transcription factors are kept inactive in the cell cytoplasm by binding to IKB (NFKB inhibitor).
L'attivazione di NFKB à ̈ regolata da IKK (IKB chinasi) che consiste di tre subunità : IKK alfa, IKK beta e IKK gamma, le prime due, dopo l'attivazione regolata dalla subunità gamma, effettuano in modo indipendente la fosforilazione di IKB, promuovendone là degradazione ad opera del pròieosoma ed il rilascio di NFKB nel nucleo dove si lega al DNA e promuove la sintesi di mRNA che esprimono enzimi antistress ossidativo, molecole di adesione, citochine pro-infiammatorie, proteine antiapoptotiche, proteine coinvolte nel ciclo cellulare. The activation of NFKB is regulated by IKK (IKB kinase) which consists of three subunits: IKK alpha, IKK beta and IKK gamma, the first two, after activation regulated by the gamma subunit, independently carry out the phosphorylation of IKB , promoting its degradation by the pròieosome and the release of NFKB in the nucleus where it binds to DNA and promotes the synthesis of mRNA which express oxidative anti-stress enzymes, adhesion molecules, pro-inflammatory cytokines, anti-apoptotic proteins, proteins involved in the cell cycle.
IKK alfa e IKK beta sono due chinasi indipendenti: la IKK alfa oltre a fosforilare la IKB alfa, trasloca nel nucleo dove potenzia l’azione di NFKB e inoltre fosforila Listone H3, promuovendo l’accessibilità di NFKB ai promotori specifici. IKK alpha and IKK beta are two independent kinases: IKK alpha, in addition to phosphorylating IKB alpha, translocates to the nucleus where it enhances the action of NFKB and also phosphorylates Listone H3, promoting the accessibility of NFKB to specific promoters.
La novità risiede nel fatto di aver trovato che la molecola del (2-(N-Acetil)-L-fenilalanilamido-2-deossi-beta-D-glucosio) : The novelty lies in the fact of having found that the molecule of (2- (N-Acetyl) -L-phenylalanyl-starch-2-deoxy-beta-D-glucose):
1) inibisce selettivamente la fosforilazione di IKB alfa da parte di IKK alpha e non di IKK beta; 1) selectively inhibits IKB alpha phosphorylation by IKK alpha and not IKK beta;
2) inibisce l’autofosforilazione di IKK alfa; 2) inhibits IKK alpha autophosphorylation;
3) inibisce la traslocazione di IKK alfa nel nucleo e depotenzia la trascrizione effettuata da NFKB; 3) inhibits the translocation of IKK alpha into the nucleus and depotentiates the transcription performed by NFKB;
4) inibisce la fosforilazione delFistone H3 da parte dell’ IKK alfa determinando un abbattimento della trascrizione. 4) inhibits the phosphorylation of Fistone H3 by IKK alpha causing a reduction of transcription.
Quindi, in parole più semplici, la molecola, oggetto della presente domanda di brevetto, possiede caratteristiche di inibitore selettivo della chinasi IKK alfa. L’azione della molecola produce rinibizione dell’attività regolatoria del fattore di trascrizione NFKB, l’inibizione della traslocazione della chinasi IKK alfa dal citoplasma al nucleo nonché Γ inibizione della azione facilitatrice della IKK alfa sulla regolazione genica effettuata dall’NFicB. Pertanto la suddetta molecola si prospetta come molecola con attività antiinfìammatoria per i suoi effetti antagonistici nei confronti di NFKB. Therefore, in simpler words, the molecule, object of the present patent application, possesses characteristics of a selective inhibitor of the IKK alpha kinase. The action of the molecule produces re-inhibition of the regulatory activity of the transcription factor NFKB, the inhibition of the translocation of the IKK alpha kinase from the cytoplasm to the nucleus as well as the "inhibition of the facilitating action of the IKK alpha on the gene regulation carried out by the ™ NFicB. Therefore the aforesaid molecule promises to be a molecule with anti-inflammatory activity due to its antagonistic effects towards NFKB.
Queste azioni sono dovute alla particolare struttura del composto ed in particolare alla N-acetil-L-fenilalanina legata con legame carboammidico al 2-ammino-2-deossi-beta-D-glucosio, Fig.l, nonché a tutte le molecole di 2-ammino-2-deossi-beta-D-glucosio che in posizione 2 hanno legati al gruppo amminico con legame carboammidico un amminoacido, un N-acil derivato di altro amminoacido o un N-acil derivato di un peptide. These actions are due to the particular structure of the compound and in particular to the N-acetyl-L-phenylalanine linked with carboamide bond to the 2-amino-2-deoxy-beta-D-glucose, Fig. 1, as well as to all the molecules of 2-amino-2-deoxy-beta-D-glucose which in position 2 have an amino acid, an N-acyl derivative of another amino acid or an N-acyl derivative of a peptide linked to the amino group with carboamide link.
Vantaggi rispetto alla tecnica precedente. Advantages over the previous technique.
La presente invenzione presenta il vantaggio di essere un inibitore selettivo della IKK alfa. The present invention has the advantage of being a selective inhibitor of IKK alpha.
Come à ̈ noto, nelle croniche, come per esempio l’osteoartrìte, sono disponibili solo farmaci non curativi ma farmaci che alleviano il dolore. La presente invenzione potrebbe essere curativa in quanto antagonizza la fonte principale del processo infiammatorio. As is well known, in chronic patients, such as osteoarthritis, only non-curative drugs are available, but drugs that relieve pain. The present invention could be curative as it antagonizes the main source of the inflammatory process.
L’invenzione si colloca nel campo scientifico della farmacologia ed in quello applicativo della fabbricazione di molecole terapeutiche. The invention is placed in the scientific field of pharmacology and in the application field of the manufacture of therapeutic molecules.
L’invenzione viene di seguito descritta, a scopo illustrativo e non limitativo, tacendo riferimento alle Figure allegate: The invention is described below, for illustrative and non-limiting purposes, without reference to the attached Figures:
Fig. 1 - Struttura del del 2-(N-acetil)-L-femlalanilamido-2-deossibeta-D-glucosio. : Fig. 1 - Structure of 2- (N-acetyl) -L-femlalanilamido-2-deoxybeta-D-glucose. :
Fig. 2 - Schema relativo alle vie intracellulari controllate dal fattore NFKB . Fig. 2 - Scheme relating to the intracellular pathways controlled by the NFKB factor.
Fig. 3 - Via di sintesi del 2-(N-acetil)-L-fenilalanilamido-2-deossibeta-D-glucosio. Fig. 3 - Synthesis pathway of 2- (N-acetyl) -L-phenylalanyl starch-2-deoxybeta-D-glucose.
La Fig. 1 riporta la struttura del 2-(N-acetil)-L-fenilalanilamido-2-deossi-beta-D-glucosio in cui la N-acetil-L-fenilalanina à ̈ legata con legame carboammidico al gruppo amminico in posizione 2 del 2-deossi-beta-D-glucosio. Fig. 1 shows the structure of 2- (N-acetyl) -L-phenylalanyl starch-2-deoxy-beta-D-glucose in which N-acetyl-L-phenylalanine is carboamide bonded to the amino group in position 2 of 2-deoxy-beta-D-glucose.
Nello schema di Fig. 2 à ̈ riportata la regolazione intracellulare effettuata dal fattore NFKB. Quest’ultimo nel citoplasma à ̈ legato all’ inibitore specifico IKB alfa ed in tal modo reso inattivo. La sua attivazione à ̈ effettuata dall’ IKK alfa, chinasi specifica che fosforila ΓΙΚΒ alfa che in tal modo può essere ubiquitinato, UB, e degradato nel proteosoma, liberando le subunità p50 e p65 del fattore NFKB che possono quindi entrare nel nucleo e promuovere, dopo legame al DNA, la sintesi di mRNA che esprimono enzimi antistress ossidativo, molecole di adesione, citochine pro-infiammatorie, proteine antiapoptotiche, proteine coinvolte nel ciclo cellulare, M. Inoltre, la chinasi IKK alfa può entrare nel nucleo dove potenzia l’azione di NFKB, nonché, fosforila l’istone H3 promuovendo l’accessibilità di NFKB ai promotori specifici. Poiché la molecola inibisce selettivamente la chinasi IKK alfa, indicato nella Fig. 2, con 1 e 2, blocca il flusso delle funzioni su citate. La molecola, oggetto dell’invenzione presentata, per la: quale viene richiesto il brevetto, risulta essere in grado di effettuare una terapia delle affezioni croniche regolate dal fattore NFKB. The diagram of Fig. 2 shows the intracellular regulation carried out by the NFKB factor. The latter in the cytoplasm is linked to the specific inhibitor IKB alpha and thus rendered inactive. Its activation is carried out by IKK alpha, a specific kinase that phosphorylates Î "Î ™ ΚΠ'alpha which in this way can be ubiquitinated, UB, and degraded in the proteasome, releasing the p50 and p65 subunits of the NFKB factor which can then enter the nucleus and promote, after binding to DNA, the synthesis of mRNA expressing oxidative anti-stress enzymes, adhesion molecules, pro-inflammatory cytokines, anti-apoptotic proteins, proteins involved in the cell cycle, M. In addition, the IKK alpha kinase can enter the nucleus where it enhances the action of NFKB, as well as phosphorylates histone H3 promoting the accessibility of NFKB to specific promoters. Since the molecule selectively inhibits the IKK alpha kinase, indicated in Fig. 2, with 1 and 2, it blocks the flow of the aforementioned functions. The molecule, object of the invention presented, for which the patent is requested, is capable of carrying out a therapy of chronic diseases regulated by the NFKB factor.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2009A000369A IT1398363B1 (en) | 2009-07-16 | 2009-07-16 | ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2009A000369A IT1398363B1 (en) | 2009-07-16 | 2009-07-16 | ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITRM20090369A1 true ITRM20090369A1 (en) | 2011-01-17 |
| IT1398363B1 IT1398363B1 (en) | 2013-02-22 |
Family
ID=41600373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITRM2009A000369A IT1398363B1 (en) | 2009-07-16 | 2009-07-16 | ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1398363B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020058889A1 (en) * | 2018-09-20 | 2020-03-26 | Cartilago S.R.L. | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5793994A (en) * | 1980-12-02 | 1982-06-11 | Nippon Chemiphar Co Ltd | Novel glucosamine derivative, its preparation, and remedy for peptic ulcer containing the same |
| CN101343313A (en) * | 2008-09-03 | 2009-01-14 | 南京农业大学 | Glucose dipeptide compounds, preparation method and application thereof |
-
2009
- 2009-07-16 IT ITRM2009A000369A patent/IT1398363B1/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5793994A (en) * | 1980-12-02 | 1982-06-11 | Nippon Chemiphar Co Ltd | Novel glucosamine derivative, its preparation, and remedy for peptic ulcer containing the same |
| CN101343313A (en) * | 2008-09-03 | 2009-01-14 | 南京农业大学 | Glucose dipeptide compounds, preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| DOHERTY DAVID G ET AL: "Amino acid derivatives of D-glucosamine", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, NEW YORK, USA, vol. 75, no. 14, 1 July 1953 (1953-07-01), pages 3466 - 3468, XP009129110, ISSN: 0002-7863 * |
| GIORDANO C ET AL: "Synthesis and properties of d-glucosamine N-peptidyl derivatives as substrate analog inhibitors of papain and cathepsin B", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 26, no. 8, 1 November 1991 (1991-11-01), pages 753 - 762, XP023870484, ISSN: 0223-5234, [retrieved on 19911101] * |
| OYA, MASANAO ET AL: "Synthesis of N-tripeptidyl-D-glucosamine by the stepwise reaction of N-carboxy .alpha.-amino acid anhydride", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN , 57(2), 439-41 CODEN: BCSJA8; ISSN: 0009-2673, 1984, XP002567361 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020058889A1 (en) * | 2018-09-20 | 2020-03-26 | Cartilago S.R.L. | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same |
| US11685760B2 (en) | 2018-09-20 | 2023-06-27 | Cartilago S.R.L. | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1398363B1 (en) | 2013-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fang et al. | Mechanosensing and mechanoregulation of endothelial cell functions | |
| Bellaye et al. | Heat shock proteins in fibrosis and wound healing: good or evil? | |
| Chen et al. | Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway | |
| He et al. | Micro‐vesicles derived from bone marrow stem cells protect the kidney both in vivo and in vitro by microRNA‐dependent repairing | |
| Zhang et al. | Recent advance in the relationship between excitatory amino acid transporters and Parkinson’s disease | |
| Li et al. | Salvianolic acid B attenuates rat hepatic fibrosis via downregulating angiotensin II signaling | |
| van de Vrie et al. | MicroRNA involvement in immune activation during heart failure | |
| Tao et al. | p62 as a therapeutic target for tumor | |
| Distefano et al. | Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure | |
| Zhang et al. | Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes | |
| González-Reyes et al. | Astrocyte s RAGE: more than just a question of mood | |
| Chen et al. | The evolving roles of pericyte in early brain injury after subarachnoid hemorrhage | |
| Li et al. | Pannexin-1 channels and their emerging functions in cardiovascular diseases | |
| Kotiyal et al. | Epithelial mesenchymal transition and vascular mimicry in breast cancer stem cells | |
| Yu et al. | Inhibition of TRPM7 channels prevents proliferation and differentiation of human lung fibroblasts | |
| Liang et al. | The unfolded protein response as regulator of cancer stemness and differentiation: Mechanisms and implications for cancer therapy | |
| Wang et al. | Lin28: an emerging important oncogene connecting several aspects of cancer | |
| Babu et al. | RNA-stabilizing proteins as molecular targets in cardiovascular pathologies | |
| Ding et al. | Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis | |
| Jiang et al. | Role of Stat3 in NLRP3/caspase‐1‐mediated hippocampal neuronal pyroptosis in epileptic mice | |
| Sun et al. | Upregulation of miR-215 exerts neuroprotection effects against ischemic injury via negative regulation of Act1/IL-17RA signaling | |
| Chen et al. | Aptamer-functionalized binary-drug delivery system for synergetic obesity therapy | |
| Dong et al. | Aging attenuates cardiac contractility and affects therapeutic consequences for myocardial infarction | |
| ITRM20090369A1 (en) | ANTAGONIST MOLECULE OF ACUTE AND CHRONIC INFLAMMATORY PROCESSES | |
| Yang et al. | Central role of purinergic receptors with inflammation in neuropathic pain-related macrophage-SGC-neuron triad |